NANOBOTS THERAPEUTICS
Contact information
- Drug delivery
- Oncology
The mission of the company is to develop and commercialize MotionTx, a revolutionary platform technology developed by the leading scientist Samuel Sánchez at IBEC that offers unique delivery capabilities and novel forms os treatments of diseases such as Bladder Cancer, among others. We aim at improving current treatments of Bladder Cancer, reducing the side effects, hospitalization costs and improving the quality of life from patients.
Our lead product (NBT-101) is at discovery-stage for non-muscle-invasive bladder cancer (NMIBIC). Bladder cancer has the highest recurrence (60%) and is the most expensive to treat ($187.000 lifetime cost per patient) due to the poor efficacy of current therapies and the difficulty of drugs to reach the tumor urothelium. NBT-101 is a urea-powered biocompatible nanorobor that can effectively deliver drugs into the tumor urothelium.
Other products are being investigated to effectively cross biological barriers in other types of cancer.
Co-development with pharma industry for NBT-101 development and other products. We seek for partners that can provide proprietary APIs to be conjugated with our delivery platform.